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Summary-The adrenal cortical enzyme systems, I ID-hydroxylase, P-450,,,, and the side-chain cleavage 
complex, P-450 see, differ only in their cytochrome P-450s. Structural modifications of metyrapone, an 
inhibitor of cytochrome P-450 enzyme systems, have been made to determine the requirement for the A- 
or B-pyridyl ring for inhibition of P-450,,, and P-450 see activities. Three new analogs of metyrapone 
(A-phenylmetyrapone, B-phenylmetyrapone and diphenylmetyrapone) were synthesized and evaluated as 
inhibitors using a crude, defatted bovine adrenal cortical mitochondrial preparation. Characterization of 
the mitochondrial preparation demonstrated: (1) enhancement of both activities by the addition of 
15.0 PM adrenodoxin, (2) the addition of 1% ethanol decreased both activities less than lo%, and (3) the 
apparent K,,, of deoxycorticosterone for P-450,,, was 6.8pM and the apparent K,,, of cholesterol for 
P-450 see was 21.6 PM. Inhibition of P-450,,, and P-450s~~ activities with these compounds demon- 
strated: (1) the B-pyridyl ring of metyrapone is required for inhibition of both activities whereas 
requirement for the A-ring is less stringent, and (2) the four metyrapone analogs were more selective 
inhibitors of P-450,,, activity. These studies suggest that the A-phenyl metyrapone analog is a good 
candidate for further development of a selective adrenocortical radiopharmaceutical. 
INTRODUCTION 
The adrenal cortex has a unique enzymatic pattern 
that is directed towards the synthesis of various 
steroids from cholesterol [I, 21. Of the enzymes in 
these pathways, both the ll/?-hydroxylase and the 
side-chain cleavage enzyme systems are found almost 
exclusively in the adrenal cortex [l, 21. The 
1 lp-hydroxylase enzyme system, P-450,,,, can cata- 
lyze the 1 l/3-, 18-, and 19-hydroxylations of various 
types of steroids [3-51, however, P-450,,, activity is 
usually characterized with the substrate 
1 I-deoxycorticosterone (DOC). The side-chain cleav- 
age enzyme system, P-450 see, catalyzes the side- 
chain cleavage of cholesterol to pregnenolone [2, 61. 
Both enzyme systems are similar in that they are 
composed of: (1) adrenodoxin reductase, a flavo- 
protein, (2) adrenodoxin, an iron-sulfur protein, and 
(3) cytochrome P-450, a heme protein. However, the 
cytochrome P-450s of the two enzyme systems are 
immunologically distinct [4]. 
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Metyrapone (Table l), 2-methyl-1,2-di-(3-pyridyl)- 
I-propanone, is a pyridine derivative that has been 
widely used to determine pituitary ACTH reserve 
[2, 3, 7,8]. Metyrapone inhibits the activity of various 
cytochrome P-450 requiring enzyme systems by re- 
versibly binding to the specific cytochrome P-450’s 
[3,7,9-131. Of the four major cytochrome P-450 
requiring enzyme systems within the adrenal cortex, 
the mitochondrial enzymes, P-450,,, and P-450 see, 
have been reported to be inhibited by metyrapone 
[3, 13-161 whereas the microsomal enzymes, the ste- 
roid 21 -hydroxylase and the 17c( -hydroxylase were 
reported not to be inhibited by metyrapone 
[13, 15-181. This is apparently the case for the en- 
zymes in the adrenal cortex of man, bovine and rat, 
but some species differences are suggested by the 
report of metyrapone binding to the adrenal cortical 
microsomes in the guinea pig [18]. Metyrapone, how- 
ever, has been primarily shown, both in vivo and in 
vitro, to be more specific for the inhibition of P-450,,, 
activity [l, 2, 3, 71. 
We have been interested in developing a radio- 
iodinated metyrapone analog that would concentrate 
in the adrenal cortex based on its selective inhibition 
of P-450,,, activity [19]. A program has been under- 
taken to systematically alter the structure of the 
metyrapone molecule to probe those structural 
features necessary for the differential inhibition of 
P-450, ,p and P-450 see. Another objective is to deter- 
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Table 1. Structure-activity relationship study: requirement for the A- or 
B-pyridyl ring in metyrapone for inhibition of bovine adrenal cortical mito- 
chondrial P-450,,8 and B~45Oscc activities (determination of the IC,, (PM)*) 
Compound 
No. Compound name x Y P-450, ,fl P-450 see 
1 Metvraoone N N 7.8 330. I 
2 A-Phen$metyrapone C N 3.3 73.3 
3 B-Phenylmetyrapone N C 64.0 392.9 
4 Diphenvlmetvrapone c c 862.9 1152.7 
*ICs, is the PM concentration of the inhibitor to give 502, inhibition. The 
correlation coefficients were greater than 0.97. 
mine the optimal site for incorporation of an iodine 
atom which still maintains this differential inhibition. 
In this study, we have investigated the requirement 
for the A- or B-pyridyl ring of metyrapone for 
inhibition of the two activities by systematically 
substituting the pyridyl rings with phenyl rings with- 
out altering the rest of the metyrapone structure 
(Table 1). 
ide, acetonitrile, propylene glycol and acetone were 
purchased from Aldrich Chemical Co., Milwaukee, 
WI. All other chemicals were the best commercially 
available grades. 
For this study, we wanted to use a simple prepara- 
tion, containing both P-450,,, and P-450 see activ- 
ities, to evaluate the metyrapone analogs. We, there- 
fore, decided to use a crude, defatted bovine adrenal 
cortical mitochondrial preparation as previously 
described [14]. Attempts to use this preparation were 
unsuccessful due to little enzymatic activity in the 
preparation. We, therefore, report the character- 
ization of a simple adrenocortical preparation for the 
rapid screening of inhibitors of P-450, ,,, and P-450 see 
activities. Using this preparation, we determined that 
the A-pyridyl ring of metyrapone replaced with a 
phenyl ring would be a good candidate for radio- 
iodination. 
The following radiochemicals were obtained from 
New England Nuclear, Boston, MA: [1,2-3H(N)]- 
DOC, 41.8 Ci/ mmol; [1,2-3H(N)]corticosterone, 
40.0 Ci/mmol; [ 1 ,2-3H(N)]cholesterol, 40.7 Ci/mmol; 
and [4-‘4C]pregnenolone, 55.7 mCi/mmol. Liquifluor, 
the PPO-POPOP toluene concentrate, was also 
purchased from New England Nuclear. 
Metyrapone analogs 
Elemental analyses were performed by Spang 
Microanalytical Laboratory, Eagle Harbor, Michi- 
gan. Infrared spectra were recorded on a Beckman 
IR Aculab 8 spectrophotometer. Nuclear magnetic 
resonance spectra were recorded on a Varian EM- 
360A spectrophotometer. Ultraviolet spectra were 
recorded on a Beckman Model 35 Dual Beam 
UV/Visible spectrophotometer. All melting points 
were taken on a Laboratory Devices Mel-temp capil- 
lary melting point apparatus and are uncorrected. 
Chemicals, radiochemicals and materials 
The following chemicals were purchased from 
Sigma Chem. Co., St Louis, MO: bovine serum 
albumin (BSA), corticosterone, DOC, 1 %hydroxy- 
DOC, EDTA, cholesterol, pregnenolone, proges- 
terone, NADPH, Tween-20, Sephadex LH-20-100, 
Sephadex G-75- 120, DEAE-cellulose and DEAE- 
Sephacel. N,N-dimethylformamide was obtained 
from Mallinckrodt, St Louis, MO; dithiothreitol 
from Calbiochem-Behring, San Diego, CA; What- 
man K6F silica1 gel glass TLC plates, 20 x 20 cm, 
250~, from Anspec Co., Ann Arbor, MI; Econo- 
columns, polypropylene, 0.8 x 4.0 cm, from Bio- 
Rad, Richmond, CA; and polypropylene tubes 
(Falcon), 12 x 75 cm, from American Scientific Prod- 
ucts, McGaw Park, IL. Trilostane (WIN-25, 540: 
2u-cyano4a,5-epoxy-l7a-hydroxy-androstane-3-one) 
was a generous gift from Sterling Winthrop CO., 
New York. Ethyl nicotinate, benzyl cyanide, tert- . . . . 
Metyrapone (2-methyl-1,2-di-(3-pyridyl)-l-propa- 
none), compound 1, was a generous gift from Ciba- 
Geigy, Inc., Summit, NJ. The A-phenylmetyrapone 
(2-methyl- 1 -phenyl-2-(3-pyridyl)- I-propanone), com- 
pound 2, was synthesized as described by Hays 
et al.[19]. Diphenylmetyrapone (2-methyl-1,2-di- 
phenyl- 1-propanone), compound 4, was synthesized 
as described by Landgrebe and Kirk[20]. 
B-Phenylmetyrapone (2-methyl-2-phenyl-1-(3- 
pyridyl)- I-propanone), compound 3 was synthesized 
by a three step synthesis. Ethyl nicotinate, and benzyl 
cyanide, were treated with sodium ethoxide in abso- 
lute ethanol to yield the enol, which was hydrolysed 
and decarboxylated to produce the ketone as first 
described by Burger and Walter[21]. The hydro- 
bromide salt of ketone (1.0 g, 0.0036 mol) was 
dissolved in 20 ml tert-butanol under an argon atmo- 
sphere with mechanical overhead stirring. Potassium 
tert-butoxide (1.23 g, 0.011 mol, 3.05 eq.) was added 
and the solution turned a bright vellow and was butanol, potassium tert-butoxide, methylene chlor- 
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heated to 85°C for 5 h. Methyl iodide (1.12 g, 0.49 ml, 
0.0079 mol, 2.2 eq.) was added to 2 ml tert-butanol 
and the solution was added dropwise over a 1 h 
period. The reaction was heated and stirred an addi- 
tional 18 h. The reaction was cooled and partitioned 
between water and methylene chloride. The methyl- 
ene chloride layer was dried, filtered and concen- 
trated under reduced pressure. The residue (0.71 g) 
was placed on a silica gel column (15 x 130 mm) and 
eluted with 200 ml ethyl acetate-methylene chloride 
(1: 19 v/v). The residue (0.60 g) was taken up in 1 .O ml 
acetonitrile and chromatographed on a Whatman 
Partisil M9, 10 mm x 50cm, ODS-2, reverse phase 
preparative HPLC column, eluted with water- 
acetonitrile (4.5:5.5, v/v) at a flow rate of 10 ml per 
min. 2-Phenyl- I-(3-pyridyl)- 1 -propanone was eluted 
and collected from the column first followed by 
the desired compound 3 with retention times of 8.32 
and 11.92 min respectively. After removal of the 
acetonitrile, the aqueous eluant was extracted with 
methylene chloride. The methylene chloride layer was 
dried, filtered and concentrated under reduced pres- 
sure to yield the dimethyl ketone (0.176 g, 21.7%) as 
a clear oil. The infrared spectra (neat) was 1675 cm-’ 
(C = 0), 1384, 1362 (gem dimethyl). The ‘H nuclear 
magnetic resonance spectra (CDCl,) was c 1.59 
(s, 6H, CHj), 7.07 (m, lH, aromatic) 7.32 (s, 5H, 
aromatic), 7.76 (m, IH, aromatic), and 8.56 (m, 2H, 
aromatic). The product was converted to its bright 
yellow picrate salt (melting point of 127-128°C) 
for elemental analysis. Analysis calculated for 
C15H15NOC6H3N107: C, 55.51; H, 3.99; and N, 
12.33. Found: C, 55.58; H, 4.05; and N, 12.38. The 
monomethylated ketone (1.74 g, 23.2x), as described 
by Napoli and Counsel1 [14], was also isolated. 
Preparation of the crude, defatted bovine adrenal 
cortical mitochondrial P-450 enzymes 
Adrenal cortical mitochondria were isolated, 
lyophilized, and defatted by a modification of the 
methods of Nedergaard and Canon[22] and Napoli 
and Counsell[l4]. Bovine adrenal glands were ob- 
tained fresh from a local slaughterhouse. Cortical 
tissue was cleaned free of fat, capsule and connective 
tissue and separated from medulla. The tissue was 
diced and homogenized (1: 10) in 0.25 M sucrose 
containing 10 mM potassium phosphate buffer, pH 
7.40, O.lOmM EDTA, 0.5% BSA, and 0.5mM 
dithiothreitol at 4°C. The homogenate was centri- 
fuged at 1,OOOg for 10 min at 5°C in a Beckman J-21 
C centrifuge. After filtration through cheesecloth, the 
supernatant was centrifuged at 10,OOOg for 10min. 
The resultant mitochondrial pellet was washed twice 
with homogenization buffer and the washed pellet 
was resuspended into 10% of the original volume of 
homogenization buffer without EDTA, BSA, or 
dithiothreitol. This suspension was lyophilized, and 
the evacuated flasks were flushed with argon and 
stored in a dessicator at -50°C. The moisture-free 
mitochondrial powder was homogenized in cold 
acetone, -2O”C, (250 mg powder per 25 ml) to ex- 
tract endogenous steroids and centrifuged at 20,000 g 
for 5 min at - 5°C. The pellet was washed twice with 
the same volume of cold acetone. The precipitate was 
collected by vacuum filtration and dried under N,, 
followed by dessication in vacua over potassium 
hydroxide at -50°C. Immediately prior to use, the 
acetone powder was reconstituted by suspension into 
30% propylene glycol(l2.0 mg powder per 400 ~1) by 
homogenization at 4°C. Using the method of 
Peterson[23] with BSA as the standard, the protein 
content of the acetone powder was determined to be 
1.64 mg protein per 12.0 mg of the acetone powder. 
Preparation of the puriJied adrenodoxin 
Adrenodoxin was purified by a modification of the 
methods of Kimura and Suzuki[24] and Kimura et 
a1.[25]. All procedures were carried out at 5°C unless 
stated otherwise. All buffer solutions were 10 mM 
sodium phosphate, pH 7.40, containing either 0, 170, 
300 or 500mM potassium chloride (KCl). Bovine 
adrenal cortical tissue, approx 0.5 kg, was homoge- 
nized and centrifuged to give a 3000 g supernatant in 
170mM KC1 buffer. After filtering through cheese- 
cloth and diluting with 2.4 vol of cold deionized and 
redistilled water, 10 g of washed DEAE-cellulose was 
added to the diluted supernatant, and the suspension 
was stirred for 18 h. The DEAE-slurry was trans- 
ferred by siphon under 5 psi of N, to a 6.0 x 15.0 cm 
column where it was filtered through glass wool. 
After washing the packed DEAE-cellulose column 
with 1.0 1. of 170mM KC1 buffer, the adrenodoxin 
was eluted with 200 ml of 500 mM KC1 buffer. 
The pooled adrenodoxin was diluted with 2.0 vol 
of buffer with no KC1 and applied onto a DEAE- 
Sephacel column (5.0 x 30.0 cm) which was equili- 
brated with 170mM KC1 buffer. After eluting the 
column with 1.5 column vol of the 170 mM KC1 
buffer, the adrenodoxin was eluted with 300 mM KC1 
buffer at the rate of approx 50 ml per h. Fractions of 
10 ml were collected. The active fractions were pooled 
and concentrated to approx 10 ml by ultrafiltration in 
a 402-ml and then a 52-ml Diaflo cell with a YM-5 
membrane (Amicon Corp., Lexington, MA) at a 
working pressure of 20 psi of N,. 
The concentrated enzyme solution was applied to 
a G-75 Sephadex column (3.0 x 100.0 cm) which was 
equilibrated with buffer with no KCl. The adreno- 
doxin was eluted with buffer at a rate of 40 ml per h. 
Fractions of 5 ml were collected. The active fractions 
were pooled, lyophilized and stored in a dessicator 
at -50°C. The final preparation was approx 90% 
homogeneous with an A,,,-A,,, ratio of 0.770. The 
yield was approx 100 mg. 
Assay of P-450,,, activity 
This cytochrome P-450 requiring enzyme system 
was assayed with DOC as the substrate by a 
modification of the method of Sato et af.[3]. Using 
5 ml polypropylene tubes, the reaction mixture, 
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0.50 ml, was modified to contain 50 mM potassium 
phosphate buffer, pH 7.40, 200pM DOC (O.lOpCi 
[ 1 ,2-3H(N)]DOC), 16 mM magnesium chloride, 
1.5 mM NADPH, 4.6% propylene glycol, 15.0 PM 
adrenodoxin, and 300 pg of the crude, defatted mito- 
chondrial preparation. The reaction mixture was 
preincubated at 37°C for 5 min, and the reaction was 
initiated by the addition of NADPH and incubated 
for various times at 37°C. Reaction controls were 
done in the absence of NADPH or in the presence of 
a heat-inactivated mitochondrial preparation where 
the preparation was heated at 8OC for 3-5 min. The 
reaction was terminated by the addition of 3.0 ml 
of methylene chloride containing 5 pg/ml each of 
DOC and corticosterone and vortexed for 30 s. After 
extracting and discarding the aqueous phase, the 
organic phase was dried down overnight at 3O‘C 
under room atmosphere. 
The residue was re-extracted with 100 ~1 of IOOO,:, 
methanol and applied onto Whatman K6F silica gel 
glass TLC plates (20 x 20 cm plates, 250 g, that were 
divided into 10 x 20 cm sections and prescored to 
10 x 2.5 cm) using the AIS TLC Multi-spotterTM. The 
plates were developed in chloroform-acetone (5: 1, 
v/v) for 20min at 25’C. The addition of DOC and 
corticosterone in the methylene chloride solution 
used to terminate the reaction permitted detection of 
the compounds under short wave ultraviolet light. 
Clear separation of DOC and corticosterone without 
overlap was obtained with the R, values of 0.66 and 
0.21 for DOC and corticosterone, respectively. The 
l&hydroxy-DOC was not separated from corti- 
costerone with this solvent system. Each zone was 
scraped and placed into a liquid scintillation vial. 
Methanol, 0.50m1, was added to extract the 
3H-labeled steroid from the silica. After the addition 
of 10 ml of scintillant, the vials were mixed well and 
counted in a Beckman LS 7500 microprocessor con- 
trolled liquid scintillation system. The samples were 
counted for 10min or to the preset error of 0.50%. 
The overall recovery for the methylene chloride ex- 
traction was 99% and for the methanol re-extraction 
was 72%. The amount of product formed was calcu- 
lated as described where a unit of activity is defined 
as a pmole of DOC converted to corticosterone or 
18-hydroxy-DOC per min at 37-C [3]. 
Assay of P-450s~~ activity 
This cytochrome P-450 requring enzyme system 
was assayed by a modification of the radiometric 
method of Takikawa et al.[6] and Hanukaglu and 
Jefcoate[26,27]. Using 5 ml polypropylene tubes, 
the reaction mixture, 0.20m1, was modified to con- 
tain 25mM potassium phosphate buffer, pH 7.20, 
200 PM cholesterol (0.10 PCi of [ 1,2-3H(N)]- 
cholesterol), 1 .O mM NADPH, 1.5% propylene gly- 
col, 1.25% N,N-dimethylformamide, 0.30% Tween- 
20, 15.0 PM adrenodoxin, and 300 pg of the crude, 
defatted mitochondrial preparation. The reaction 
mixture was preincubated at 37°C for 5 min, and the 
reaction was initiated by the addition of NADPH and 
incubated for various times at 37°C. Reaction con- 
trols were done in the absence of NADPH or in the 
presence of a heat-inactivated mitochondrial prepara- 
tion in which the preparation was heated at 80 ‘C for 
3-5 min. The reaction was terminated by the addition 
of 200 PI of loo;,; ethanol containing 1.0 nCi of 
[4-‘4C]pregnenolone as a recovery standard. The 
steroids were extracted with 2.0 ml of methylene 
chloride. After drying, the residue was re-extracted 
with 200~1 of 40?; methanol, and separated on 
Sephadex LH-20 in polypropylene minicolumns [26]. 
The eluted pregnenolone was collected in a liquid 
scintillation vial, and the methanol solution was 
evaporated. After the addition of 10 ml of scintillant, 
the vials were mixed well and counted in a Beckman 
LS 7500 microprocessor controlled liquid scintil- 
lation system. The samples were counted for 10 min 
or to a preset error of O.SOq;. The 3H channel was set 
at O-397 and the 14C channel was set at 397-655. The 
14C overlap into the ‘H channel was about 8%. The 
overall recovery for the methylene chloride extraction 
was 86% and for the methanol re-extraction was 71’1:‘,. 
The amount of product formed was calculated as 
described where a unit of activity is defined as a 
pmole of cholesterol converted to pregnenolone per 
min at 37’C [6,26, 271. 
Kinetic and inhibition studies 
Kinetic studies were done in the presence of 1.0% 
ethanol for the determination of the K,,, of DOC for 
P-450,,, activity and for the K,,, of cholesterol for 
P-450 see activity. The kinetic studies were analyzed 
by the mathematical form of the Lineweaver-Burk 
double-reciprocal equation. The K,,, values are the 
mean of three separate determinations. 
Stock solutions of the inhibitors were made in 
100% ethanol. Inhibitors were added to the reaction 
mixtures of each assay prior to the addition of 
NADPH such that a final concentration of 1% 
ethanol was added. Using controls in the presence of 
1% ethanol, the percent inhibition, at varying concen- 
trations of each inhibitor, was calculated. The IC,, 
(PM) values were obtained from the linear portion of 
semi-logarithmic plots of percent inhibition vs con- 
centration. Two separate determinations with five or 
more inhibitor concentrations were evaluated in trip- 
licate in all ICsO (PM) determinations. Regression 
lines were calculated by least square analyses and the 
correlation coefficients were greater than 0.97. 
RESULTS 
.Efect qf added adrenodoxin 
A crude, defatted bovine adrenal cortical mito- 
chondrial preparation was used so that both activities 
might be studied without purification of the protein 
components of these enzyme systems. However, adre- 
nodoxin is a loosely bound mitochondrial protein 
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Fig. 1. Effect of added adrenodoxin to a defatted bovine adrenal cortical mitochondrial preparation on 
P-450,,, and P-450 see activities. A. P-450,,, activity, in the absence (-H-) or presence (-a-) of 
15.0pM adrenodoxin. B. P-450 see activity, in the absence (-¤--) or presence (-a---) of 15.0pM 
adrenodoxin. The points shown are the mean of triplicate determinations and are typical of three such 
experiments. 
[24,25] which might be lost upon preparation of the 
defatted mitochondria. Since this loss would lead to 
decreased P-450,,, and P-450 see activities and de- 
creased sensitivity to the inhibition of these activities 
by the metyrapone analogs, adrenodoxin was purified 
to approx 90% homogeneity. The addition of 
15.0 PM adrenodoxin to this preparation enhanced 
both P-450,,, and P-450 see activities (Fig. 1A and B). 
In the presence or absence of adrenodoxin, both 
activities were linear with time and mitochondrial 
protein. In this particular preparation, the specific 
activity of P-450,,, and P-450s~~ was 2,906.9 and 
2,761.9 units/mg mitochondrial protein, respectively, 
in the presence of 15.0/*M adrenodoxin. The addi- 
tion of trilostane, an inhibitor of 3B-hydroxysteroid 
dehydrogenase[28], to the reaction mixtures of P- 
450s~~ did not affect the activity with time, and 
further metabolism of the pregnenolone formed was 
not detected with this preparation. 
Efect of various organic solvents 
Since the inhibitors to be studied are lipophilic, 
especially compound 4, an organic vehicle was neces- 
sary to deliver the inhibitors into the reaction mix- 
tures. As shown in Figs 2A and B, the addition of 
ethanol, N,N-dimethylformamide and n-propanol 
decreased both P-450, ,b and P-450 see activities. The 
addition of propylene glycol was well tolerated in the 
P-450s~~ activity assay, but it markedly decreased 
P-450,,, activity at concentrations greater than 3%. 
N-Propanol and several other organic solvents were 
observed to be poorly tolerated and similarly 
decreased both enzymatic activities to 20% of the 
control levels at concentrations of 2%. Since ethanol 
was slightly better tolerated than N,N-dimethyl- 
formamide in both assays, it was selected as the 
organic vehicle. Ethanol, at lx, gave 92 and 100% of 
the control assays for P-450,,, and P-450 see re- 
spectively in the absence of added organic solvent. 
No differences were observed in the presence or 
absence of 15.0 p M adrenodoxin. 
Determination of the kinetic constants 
As further evidence that this crude preparation 
could be used to study the inhibition of both activ- 
ities, we determined the apparent Km of DOC for 
P-450,,, was 6.8 PM (Fig. 3A), and the apparent K,,, 
of cholesterol for P-450 see was 21.6 PM (Fig. 3B). 
loo..-¤-. (A) 
012345 
. --*-Mom_ . . “: 
0 4 2 34 5 
Percent solvent 
Fig. 2. Effect of various organic solvents on bovine adrenal 
cortical P-450, ,p and P-450 see activities. Effect of propylene 
glycol (-W-L ethanol (-•-). dimethylformamide 
(-_O--), and n-propanol (-_O-) on: A. P-450,,@ activity, 
and B. P-450 see activity. The points shown are the mean of 
triplicate determinations and are typical of three such 
experiments. 
108 MICHAEL C. TOBES et al. 
(A) IO- . / 
7 E B- . / \ 
0 E 6- / Q 
- 
N 





0 -, I I I I 








0-, / I I I I 
0 4 2 3# 4 5 
16’ (Deoxycortlcosterone , p Ml“ 16’ (Cholesterol, pM)mi 
Fig. 3. Determination of the apparent K, of DOC for P-450 ,,,, and cholesterol for P-450 see. Standard 
assay conditions were used in the presence of 1% ethanol. A. Effect of varying the concentration of DOC 
on P-450,,, activity. B. Effect of varying the concentration of cholesterol on P-450 see activity. The points 
shown are the mean of duplicate determinations and are typical of three such experiments. 
Although adrenodoxin has been reported to be an 
effector of cholesterol binding as well as an electron 
carrier[29], we did not observe the addition of 
15.0 MM adrenodoxin to affect the K,,, of cholesterol 
or the K, of DOC in this system. 
The inhibition of both P-450,,, and P-450 see 
activities by metyrapone, A-phenylmetyrapone, 
B-phenylmetyrapone, and diphenylmetyrapone is 
shown in Table 1. P-450,,, activity was 1.3 to 
42.3-fold more sensitive to the inhibition by the four 
metyrapone analogs than P-450 see activity as shown 
by the IC, (PM) values. Both enzyme activities 
require a pyridyl ring for inhibition. The B-pyridyl 
ring of metyrapone is required for inhibition of both 
cytochrome P-450s whereas the requirement for the 
A-pyridyi ring is less stringent. Similar results were 
obtained in the presence or absence of 15.0 PM 
adrenodoxin. 
DISCUSSION 
We have focused on the adrenocortical P-450,,, 
enzyme system for the development of a radio- 
iodinated inhibitor which would selectively 
concentrate into the adrenal cortex based on selective 
inhibition of P-450,,p activity. Although metyrapone 
will inhibit other cytochrome P-450 requiring enzyme 
systems [3,7,9-131, radiolabeled metyrapone should 
concentrate in the adrenal cortex due to: (1) a higher 
concentration of cytochrome P-450 in the adrenal 
cortex than in the liver or kidney [30], and (2) 
apparent specificity in vivo and in vitro for P- 
450,,, [1,2,3,7]. Tissue distribution studies with triti- 
ated metyrapone have further supported this 
hypothesis [31]. Since we are interested in developing 
a radioiodinated metyrapone analog, we initiated a 
program to systematically alter one region of the 
metyrapone molecule at a time to determine an 
optimal site for iodine incorporation while still main- 
taining a selective inhibition of P-450,,,{ activity to 
that of P-45Oscc activity. In this study, we syn- 
thesized three metyrapone analogs (Table 1) to deter- 
mine the requirement of the A- or B-pyridyl ring for 
inhibition of P-450, l/i and P-450 see activities. 
Several studies were done to characterize the crude, 
defatted bovine adrenal cortical mitochondrial prepa- 
ration that was used to evaluate these inhibitors. The 
enhancement of both activities by the addition of 
15.0pM adrenodoxin (Fig. 1A and B) suggests that 
considerable adrenodoxin is lost upon preparation of 
the defatted mitochondria. This is consistent with the 
observations that adrenodoxin is a loosely bound 
mit~hondrial protein [24,25]. The effect of organic 
solvents was investigated (Fig. 2A and B), not only 
because an organic vehicle is necessary to deliver the 
inhibitors into the reaction mixtures, but also because 
organic solvents were reported to affect hepatic cyto- 
chrome P-450 binding with hydrocarbon substrates 
[32]. The decreased activity observed may be the 
result of an interaction of the organic solvent with 
either or both the mitochondrial preparation and the 
substrates DOC and cholesterol. In one study, I2 mg 
of a similar mitochondrial preparation without added 
adrenodoxin was used to evaluate the inhibition of 
P-450,,{{ activity with several metyrapone analogs 
where the inhibitors, as well as DOC, were delivered 
in ethanol to give a final concentration of 4% ethanol 
[14]. This concentration of ethanol drastically re- 
duced the P-450,,, and P-450s~~ activities in our 
assays. We selected 1% ethanol, 15.0 PM adreno- 
doxin, and 300 pg of the crude, defatted mito- 
chondrial preparation for these studies to minimize 
Pyridyl ring requirement for inhibition 109 
the potential nonspecific binding of the inhibitors to 
the mitochondrial preparation and the organic inter- 
action with the inhibitors, substrates and/or mito- 
chondrial preparation. The observed apparent K, of 
6.8 PM for DOC for P-450,,, (Fig. 3A) is similar to 
that reported by others [3, 141. The observed appar- 
ent K,,, of 21.6pM for cholesterol for P-450 see 
(Fig. 3B) differs from previous reports of 120 PM [6], 
1.8 PM [33] and 5 PM [34] which may be due to the 
mitochondrial preparation used as well as the assay 
conditions [29]. 
There is limited information on the inhibition of 
P-450 see by metyrapone while the evidence regarding 
the requirement of both pyridine rings in metyrapone 
for inhibition of P-450,,, is not conclusive. A recent 
analysis of the crystal and molecular structure of 
metyrapone can not be used to predict which ring is 
important for inhibition [35], and previous studies 
simultaneously modified more than one structural 
feature of the metyrapone molecule [14,36]. This 
study is a systematic evaluation of the requirement of 
the pyridine rings (Table 1). The inhibition of P- 
450,,,$ and P-450 see activities by these metyrapone 
analogs demonstrates a requirement for at least one 
pyridyl ring since diphenylmetyrapone is the poorest 
inhibitor of both activities. Since the inhibition of 
P-450,,, activity by B-phenylmetyrapone was 8- to 
19-fold less effective than A-phenylmetyrapone or 
metyrapone, the B-pyridyl ring of metyrapone is 
required for inhibition of P-450,,, activity whereas 
the requirement for the A-pyridyl ring is not as 
stringent. The greater effectiveness of A- 
phenylmetyrapone to inhibit P-450 see activity also 
suggests a requirement of the B-pyridyl ring of mety- 
rapone for inhibition. The similar effectiveness of 
metyrapone and B-phenylmetyrapone to inhibit P- 
450 see activity contrasts to their effectiveness to 
inhibit P-450,,,{ activity. This may be due to a greater 
requirement for a hydrophobic region in the met- 
yrapone molecule to bind to the active site of the 
cytochrome P-450 see. The 1.3- to 42.3-fold greater 
sensitivity of P-450,,, activity than P-450 see activity 
to the inhibition of metyrapone and its A- and 
B-phenyl analogs may also reflect differences in the 
hydrophilicity of the two active-sites. 
These studies suggest some of the structural 
requirements of metyrapone for the inhibition of 
P-450,,,, and P-450 see activities and suggest that the 
A-phenylmetyrapone analog is a good candidate for 
radioiodination as a selective radiopharmaceutical 
agent for the adrenal cortex. Such an agent could be 
useful in evaluating patients with defective P-450,,, 
[37, 381. 
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